Novavax Push For COVID-19 Vaccine Manufacturing Capacity Delays Flu Vaccine Application
Executive Summary
As CEO Erck touts that its COVID vaccine has the 'best data,' Novavax prepares to enter Phase III trials and inks deal with Serum Institute to boost production even as its 'almost a perfect flu vaccine' remains on hold.
You may also be interested in...
COVID-19 Vaccine EUA Process Compresses Advisory Committee Prep Too
US FDA wants briefing documents when EUA is submitted to accommodate timely advisory committee reviews; unlike traditional assessment process, the agency does not appear interested in engaging in back-and-forth discussions with sponsors about portions of the briefing document that should be made public or redacted.
How BARDA Locked Up COVID-19 Vaccine Manufacturing Capacity For Operation Warp Speed
US agency avoided procurement delays with sole-source awards to two medical countermeasures venture partners worth nearly $900m.
Regeneron COVID-19 Therapeutic, Novavax Vaccine Get BARDA Funding To Boost Manufacturing
US government to own doses of Regeneron's investigational cocktail antibody REGN-COV2 manufactured under a $450m contract and 100 million doses of Novavax's investigational vaccine under a $1.6bn agreement.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: